旭輝永升服務(01995.HK)控股股東Elite Force折讓9%配股 涉4.37億元
旭輝永升服務(01995.HK)公布,控股股東Elite Force於二級市場上大宗交易方式配售公司合共9,000萬股予若干獨立投資者,佔公司股本總額約5.15%,每股配售價為4.85元,較昨日(14日)收市價5.33元折讓約9%,涉約4.37億元。
目前,林中、林峰及林偉(以一致方式行事),通過旭輝控股(00884.HK)、Elite Force及其控制的其他投資控股公司,有權行使公司已發行股本約51.98%的投票權,因此他們共同構成公司的一組最終控股股東。配售事項完成後,最終控股股東將有權行使公司已發行股本約46.84%的投票權,而公司將繼續作為旭輝控股的非全資附屬。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.